(Reuters) – Eli Lilly and Co will sell its low blood sugar drug Baqsimi to Amphastar Pharmaceuticals for over $500 million in cash, the two companies said on Monday.
Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
